

# Glycopeptide-intermediate *S. aureus*

## Glycopeptide-intermediate *S. aureus*

Won Kil Lee, M.D.

Department of Clinical Pathology, Kyungpook National University Hospital,  
Taegu, Korea.

가  
 , MRSA  
 VRE(vancomycin-resistant enterococci) 가  
 , CNS 가  
 ,  
 ,  
 vancomycin-intermediate *S.* CNS  
*aureus*(VISA), MIC( )가  
 8-16 ug/mL Tuazon [5] *S. epidermidis*  
 [1,2] . 4 가 MIC가  
 10 ug/mL , Siebert [6] 25  
 glycopeptide-intermediate *S.* MIC가 50ug/mL ,  
*aureus*(GISA)[3] 2 5 × 10<sup>6</sup> 1 × 10<sup>7</sup>  
 van A, B, C CFU/mL ,  
 1 × 10<sup>5</sup> CFU/mL MIC가 3.12  
 (MRSA) ug/mL .  
 glycopeptides 1987 Schwalbe [7] 37  
 ,  
 CNS(*S. haemolyticus*) 8  
 [4] . 88  
 , MRSA , 8 ug/mL 가 . 2 ug/mL  
 가 8 ug/mL BHI  
 D-alanyl-D-alanine 가 .  
 CNS( ) GISA  
 :  
 (700-422) 2가 101 *S. aureus*(VISA);  
 MIC=8ug.mL) 1996 1  
 Tel : 053-420-5292 Fax : 053-426-3367 [1] , 1997 Michigan New

Jersey 2 [2] . , selective pressure가 가  
 , GISA . , MIC가 4 ug/mL  
 2 , 59 가 .  
 , MRSA  
 23 18 CDC  
 , GISA가  
 van A, B, C  
 , ciprofloxacin, , MRSA  
 , TMP/SMX, mupirocin 가  
 CDC  
 TMP/SMX , , GISA  
 , GISA  
 66  
 MRSA 1997 2 7  
 17 11  
 , GISA가  
 MRSA  
 VRE가 가 ,  
 GISA  
 GI-CNS . GISA vancomycin-resistant *Staphylococcus aureus*가  
 16 - 18 mm  
 NCCLS 15 mm  
 ,  
 15mm microdilution test  
 MIC가 4 ug/mL  
 glycopeptide MIC가 4  
 ug/mL 0.2%,  
 MRSA 0.2%, CNS 0.6%,  
 CNS 3.4% .  
 E-strips 6-8 ug/mL  
 GISA  
 GISA MRSA ,  
 MRSA 가 ,

1. *Staphylococcus aureus* with reduced susceptibility to vancomycin--United States. *MMWR Morb Mortal Wkly Rep* 1997;22:46(33):765-6.
2. Whittle J, Queenan E. Vancomycin-resistant enterococci: improving treatments. *Pa Med* 1997;100(11):24-6.
3. Check W. Asrute setinels needed to tackle GISA strains. *CAP Today* 1998;12:5-6.
4. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Tenover FC. *Manual of Clinical Microbiology*. 6th ed. Washington, D.C. ASM Press, 1995:1293.
5. Tuazon CU, Miller H. Clinical and microbiologic aspects of serious infection caused by *Staphylococcus epidermidis*. *Scand J Infect Dis* 1983;15:347-60.
6. Siebert WT, Moreland N, William TW Jr. Synergy of vancomycin plus cefazolin or cephalothin against methicillin-resistant *Staphylococcus epidermidis*. *J Infect Dis* 1979;139:452-7.
7. Schwalbe RS, Stapleton JT, Gilligan. Emergence of vancomycin resistance in coagulase-negative staphylococci. *N Engl J Med* 1987;316:927-31.